Saturated Fat and ApoB: What the CARBFUNC Trial Reveals

For more than half a century, conventional dietary guidelines have cautioned against saturated fat. From butter and cheese to red meat, saturated fatty acids have been widely considered primary drivers of atherosclerotic cardiovascular disease (ASCVD). The established logic was simple: saturated fat increases low-density lipoprotein cholesterol (LDL-C), which accumulates within arterial walls to form plaque.

However, modern preventive cardiology increasingly focuses on a more precise biomarker: apolipoprotein B (apoB). Because every atherogenic lipoprotein particle—including LDL, very-low-density lipoprotein (VLDL), and intermediate-density lipoprotein (IDL)—carries exactly one molecule of apoB, measuring apoB quantifies the total number of circulating plaque-causing particles rather than merely the cholesterol transported inside them. This development has sparked an essential question: when dietary saturated fat increases within a low-carbohydrate eating pattern, does atherogenic particle count inevitably rise, or does metabolism handle lipids differently when carbohydrates are reduced?

A landmark clinical trial published in eBioMedicine (part of The Lancet Discovery Science) offers rare long-term human evidence on this debate. Researchers conducting a secondary analysis of the randomized controlled CARBFUNC trial tracked 193 adults over two years to observe how a low-carbohydrate, high-saturated-fat diet influences apoB and advanced lipid subfractions.

Inside the 2-Year CARBFUNC Clinical Trial

The CARBFUNC study was conducted by clinical researchers at the University of Bergen and Haukeland University Hospital in Western Norway. Rather than relying on brief feeding studies lasting several weeks, the trial followed 193 adults with obesity (BMI ≥ 30 kg/m²) over 24 months.

Participants were randomized to one of three sustainable, energy-controlled dietary patterns:

Low-Carbohydrate, High-Fat (LCHF): Saturated fatty acids supplied roughly 30% of total daily energy—more than triple standard guidelines. Total dietary fat accounted for over 70% of calories, while carbohydrates were restricted.
High-Carbohydrate, Minimally Refined: A guideline-aligned diet emphasizing intact whole grains, legumes, vegetables, and low saturated fat (under 10% of total calories).
High-Carbohydrate, Refined: A comparator group adhering to standard fat restriction while consuming customary refined carbohydrate sources.

Using nuclear magnetic resonance (NMR) spectroscopy and ultracentrifugation, investigators measured apoB, apolipoprotein A1 (apoA1), LDL particle diameters, small dense LDL (sdLDL), large buoyant LDL, VLDL particles, and remnant cholesterol.

The Central Finding: ApoB Remained Stable

The primary trial finding challenged conventional expectations. Despite consuming nearly one-third of daily calories from saturated fat for 24 months, participants in the low-carbohydrate high-fat cohort experienced no significant increase in circulating apolipoprotein B compared to those on low-fat, higher-carbohydrate diets.

Total LDL-C did rise modestly in the high-fat arm (by approximately 5% to 10%). However, detailed lipid fractionation revealed this increase was driven almost entirely by larger, buoyant LDL particles. Crucially, concentrations of small dense LDL (sdLDL)—the compact particles that most readily penetrate the arterial wall to trigger plaque formation—did not increase.

Participants in the high-fat cohort also showed notable improvements across several key secondary metabolic markers:

Triglyceride Reductions: Fasting triacylglycerols dropped significantly over 24 months.
Remnant Cholesterol Clearance: Levels of remnant cholesterol—the highly atherogenic cholesterol in partially hydrolyzed lipoproteins—declined markedly.
HDL-C and ApoA1 Elevation: High-density lipoprotein cholesterol and protective apolipoprotein A1 rose substantially.
VLDL Particle Decline: Circulating very-low-density lipoproteins decreased, signaling efficient hepatic lipid clearance.

Comparing Biomarker Shifts: CARBFUNC Trial Results

The table below summarizes the key cardiometabolic adaptations observed over 24 months across the trial cohorts.

Cardiometabolic Biomarker	High Saturated Fat Arm (~30% SFA)	Guideline Carbohydrate Arms (<10% SFA)	Clinical Significance
Apolipoprotein B (apoB)	No significant difference vs. control	Maintained at baseline levels	Total atherogenic particle concentration remained stable despite tripled saturated fat intake.
Total LDL Cholesterol (LDL-C)	Modest increase (+5% to +10%)	Slight decrease or neutral	Driven by expanded cholesterol content in larger particles rather than particle proliferation.
Small Dense LDL (sdLDL)	No significant elevation	Unchanged	Compact, easily oxidized particles linked to vascular injury did not multiply.
Large Buoyant LDL	Significant increase	Slight decrease	Particles expanded in size and volume without increasing circulating atherogenic particle count.
Fasting Triglycerides	Significant reduction	Modest reduction or stable	Reflects reduced hepatic lipogenesis and improved clearance under carbohydrate restriction.
Remnant Cholesterol	Significant decrease	Minimal change	Indicates lower circulating pools of atherogenic, triglyceride-rich remnant lipoproteins.
HDL-C & ApoA1	Significant increase	Stable or slight decrease	Enhanced reverse cholesterol transport capacity and favorable shifts in protective apolipoproteins.

Source: Adapted from Loddervik et al., eBioMedicine (The Lancet Discovery Science), October 2026; DOI: 10.1016/j.ebiom.2026.106524.

Hepatic Physiology: Why Didn’t Particle Counts Surge?

To explain why saturated fat did not elevate apoB, researchers point to hepatic lipid handling during carbohydrate restriction. When dietary carbohydrate intake drops, hepatic de novo lipogenesis decreases sharply. The liver synthesizes fewer triglycerides and secretes fewer VLDL particles into the bloodstream.

Because VLDL particles are metabolic precursors to LDL, lower hepatic VLDL output alters lipoprotein remodeling. LDL particles circulate longer to exchange lipid cargo, becoming larger and buoyant. While each particle carries more cholesterol—accounting for the modest LDL-C rise—the total number of atherogenic particles (measured by apoB) does not expand.

These findings differ from lean mass hyper-responders (LMHR), where lean individuals on ketogenic diets sometimes experience steep surges in both LDL-C and apoB. In the CARBFUNC cohort of adults with obesity consuming a sustainable whole-food diet, metabolic context dictated the lipid outcome.

Public Health Guidelines vs. Study Realities

While the CARBFUNC results provide valuable mechanistic insight, medical authorities emphasize that they must be weighed alongside established public health guidance. Major cardiology societies caution against viewing these findings as an unreserved endorsement of unlimited saturated fat.

The American Heart Association saturated fat dietary guidance advises limiting saturated fat to under 6% of daily calories for those with elevated cardiovascular risk, and under 10% for the general public. Likewise, World Health Organization healthy diet guidelines recommend replacing saturated fats with polyunsaturated and monounsaturated options to reduce population-level cardiovascular disease.

Guidance from the Centers for Disease Control and Prevention on cholesterol emphasizes that cardiovascular disease remains the leading cause of death in the United States, and individual responses to dietary fat vary widely. Individuals with familial hypercholesterolemia or specific APOE genotypes may experience substantial increases in apoB when consuming high saturated fat.

Study Limitations and Practical Takeaways

When interpreting the CARBFUNC findings, several limitations must be acknowledged:

Surrogate Biomarkers vs. Hard Outcomes: The trial tracked blood biomarkers over two years, not hard clinical endpoints like heart attacks, stroke, or mortality. Multi-decade outcome studies remain the reference standard in preventive cardiology.
The Whole-Food Matrix: Saturated fats in CARBFUNC came from whole foods like butter, cheese, and meats within an unrefined eating pattern. These results cannot be applied to ultra-processed foods combining saturated fats with refined starches and added sugars.
Study Attrition: As with any multi-year lifestyle intervention, adherence challenges over 24 months require cautious interpretation.

For individuals exploring lower-carbohydrate nutrition, the CARBFUNC trial demonstrates that lipid metabolism is far more intricate than single cholesterol tests reveal. Rather than relying solely on standard lipid panels, individuals discussing dietary adjustments with their healthcare provider may benefit from comprehensive testing—including apoB, fasting insulin, and high-sensitivity C-reactive protein (hs-CRP)—to evaluate their unique cardiovascular health.